On July 28, Pfizer rose 3.08% in regular trading, trading at $25.375/share, with turnover of $369 million. The rally was driven by a broad pharma sector uplift following GlaxoSmithKline's better-than-expected second-quarter earnings report.
GlaxoSmithKline reported adjusted earnings per share of 50.5 pence, significantly exceeding the market consensus estimate of 46.8 pence. The company also announced plans to fully achieve annual cost savings of GBP 1.9 billion by 2029, further boosting investor confidence in sector-wide profitability. The strong results triggered a rally across major pharmaceutical names, with GlaxoSmithKline up 5.62%, Merck up 2.82%, Eli Lilly up 2.53%, Johnson & Johnson up 2.45%, and AstraZeneca up 2.15%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)